OBJECTIVES: Type 2 diabetes mellitus patients (T2DM) with chronic heart failure (CHF) are at higher risk of hospitalization for HF, nonfatal myocardial infarction (MI) and renal replacement therapy (RRT). The results of the EMPA-REG OUTCOME study presented convincing evidence that the use of empagliflozin in these patients can significantly reduce the frequency of such hospitalizations. The aim of this study was to compare the clinical and economic impact of empagliflozin in combination with standard of care (SoC) vs SoC in reducing the frequency of hospitalizations in T2DM patients with CHF.

METHODS: All adult Russian T2DM patients with CHF were considered the target population totaling 106,988 people. Data from the EMPA-REG OUTCOME trial was employed to predict the number of cardiovascular and renal events that can be prevented using empagliflozin with SoC instead of placebo with SoC. The methodology described by Fleurence and Hollenbeak was used to estimate the one-year occurrence probability. This analysis was conducted from the perspective of the Russian healthcare system and costs data was derived from Russian national sources. Exchange rate was: 1 USD = 73,50 Ruble.

RESULTS: The modelling data indicates that relative to SoC, empagliflozin with SoC yielded fewer cardiovascular and renal-related hospitalizations. The use of empagliflozin with SoC in T2DM patients with CHF will allow to prevent an additional 4482 CHF-related hospitalizations, 2239 nonfatal MI-related hospitalizations and 961 RRT-related hospitalizations in 2022-2024. Significant health care budget savings can be achieved due to the decrease in the number of hospitalizations: 3,454,208 USD in 2022, 5,199,346 USD in 2023, 6,857,673 USD in 2024.

CONCLUSIONS: This analysis suggests that adding empagliflozin to standard therapy in T2D patients with CHF may provide a more effective use of healthcare resources by preventing additional hospitalizations.